Objective Currently available studies that fully analyse the metabolic parameters in patients with prolactinoma are scarce and discordant. The aim of this study was to evaluate the metabolic effects of cabergoline (CAB) treatment in patients with newly diagnosed prolactinoma in relation to disease control and CAB dosage. Design This is a retrospective clinical-based therapy analysis. Patients Forty-three patients with prolactinoma (eight men, 35 women), aged 33Á65 AE 11Á23 years, were evaluated metabolically at baseline and after 12 months of CAB treatment. Measurements Body mass index (BMI), systolic and diastolic blood pressure, waist circumference (WC), lipid profile, haemoglobinA1c (HbA1c), glucose and insulin levels (and their areas under the curve, AUC) after an oral glucose tolerance test, homoeostasis model assessment of insulin resistance (Homa-IR) index, insulin sensitivity index (ISI) Matsuda, oral disposition index (DIo) and visceral adiposity index (VAI) were measured at baseline and after 12 months of treatment. Results Twelve months of CAB reduced WC (P < 0Á001), total (P = 0Á001) and low-density lipoprotein \terol (P < 0Á001), triglycerides (P = 0Á024), fasting insulin (P < 0Á001), AUC INSULIN (P < 0Á001), HbA1c (P = 0Á022), Homa-IR (P < 0Á001) and VAI (P < 0Á001), with a concomitant increase in high-density lipoprotein cholesterol (P < 0Á001) and in ISI Matsuda (P < 0Á001), regardless of the degree of reduction in prolactin levels. The patients receiving higher doses (>0Á50 mg/week) of CAB showed lower BMI (P = 0Á009), fasting insulin (P = 0Á001), Homa-IR (P < 0Á001) and VAI (P = 0Á018) and higher ISI Matsuda (P = 0Á002) and DIo (P = 0Á011), compared with those on lower doses. Conclusions A significant metabolic improvement was observed in patients with prolactinoma after 12 months of CAB treatment, especially when higher doses were used, highlighting the importance of considering the metabolic profile in these patients and the role of active treatment with high CAB doses.
Introduction
Prolactinoma is the most frequent secreting pituitary tumour and mainly affects the female gender. 1 Besides the well-known consequences on the reproductive axis both in men and women, hyperprolactinaemia can be associated with alterations in body composition and obesity, 2 although the evidence is discordant.
Reduced bone density 3, 4 and total body fat 5, 6 have been positively associated with high prolactin (PRL) levels in patients with prolactinoma. Schmid et al. 7 demonstrated significantly higher body mass index (BMI) in patients with macroprolactinoma than both patients with inactive adenomas and the general population. Conversely, Naliato et al. showed similar body fat in women with prolactinoma and controls. 5 Dopamine agonists (DA) are recognized as the recommended therapy to lower PRL levels and decrease tumour size for patients with prolactinoma, and the use of cabergoline (CAB) is suggested in preference to other DA because of its higher efficacy. 8 Several studies have analysed the effects of DA treatment on body fat and metabolism, but most of them used mainly bromocriptine. 9 In this setting, reduced body fat content and a lower risk of metabolic syndrome have been associated with the normalization of PRL during DA treatment. 5 Decreased BMI and waist circumference (WC) have been reported during DA therapy in some studies, 10 but not in others. 11 However, currently available studies that fully analyse the metabolic parameters in patients with prolactinoma at diagnosis and during treatment with CAB are scarce, and discordant data have been reported. Based on the data that link the body composition parameters with PRL levels and DA administration, the aim of the current study was to fully evaluate the effects of 12 months of CAB treatment on the metabolic syndrome (MS), insulin
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Patients and methods
We conducted a retrospective chart review of patients affected by hyperprolactinaemia seen at the Unit of Endocrinology of the University of Palermo from 1 January 2011 to 30 October 2012. We analysed data from a total of 89 patients. The flow chart of patient distribution and inclusion in the study according to the criteria adopted is shown in Fig. 1 . Patients with hyperprolactinaemia secondary to drugs (including neuroleptics, antidepressants, opiates and gastrointestinal prokinetics) or mixed-secreting tumours, those already receiving dopamine agonists at the baseline visit and those with a followup of less than 12 months were excluded from this analysis. In addition, we excluded patients with multiple pituitary hormone deficiencies and/or the presence of other concomitant causes of overt hypogonadism to avoid the potential impact of hormonal deficit or gonadal replacement therapy on metabolic parameters. No women receiving oestrogens and/or progesterone as contraceptives or postmenopausal hormone replacement therapy were included. All patients with already known glucose abnormalities were treated with diet alone. Patients already receiving hypoglycaemic agents were excluded from this study. For the purpose of this study, we enrolled 43 consecutive patients (8 men, 19%; 35 women, 81%) aged 33Á65 AE 11Á23 years (range: 16-63), with newly diagnosed prolactinoma. The diagnosis was based on signs and symptoms of hyperprolactinaemia, high-serum PRL levels and magnetic resonance imaging (MRI) demonstrating a pituitary tumour. 8 This study was conducted in compliance with the 'Ethical principles for medical research involving human subjects' of the Helsinki Declaration. At the time of hospitalization, all patients signed a consent form for the scientific use of their data and the identity of the participants remained anonymous during the analysis.
Study design
All patients, at baseline and after 12 months of CAB treatment, underwent a complete clinical and metabolic evaluation. Prolactin levels were considered as the mean value of measurements in at least three blood samples collected at 20-min intervals for 1 h, obtained through venous cannulation, without repeated venepuncture stress. Women who presented with menstrual cycles, even if irregular, were studied in the early follicular phase (1-7 days from bleeding). In all patients, MRI revealed the presence of a pituitary tumour. Tumour volume was calculated in line with the Di Chiro and Nelson formula (volume = height 9 length 9 width 9 p/6) and was expressed as mm 3 . BMI and systolic (SBP) and diastolic (DBP) blood pressure were measured in all patients. WC was measured at the midpoint between the lower rib and the iliac crest. After an overnight fast, total, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) cholesterol, triglycerides and haemoglobinA1c (HbA1c) were measured. In addition, an oral glucose tolerance test (OGTT) was performed by measuring plasma blood glucose and insulin levels every 30 min for 2 h after a 75-g oral glucose load. The areas under the curve of glucose (AUC GLU ) and insulin (AUC INS ) during the 2-h OGTT were also calculated. The diagnosis of diabetes or glucose tolerance abnormalities was made according to the American Association of Clinical Endocrinologists medical guidelines. 13 Basal insulin resistance (IR) was assessed using homoeostasis model assessment of the insulin resistance (Homa-IR) index. 14 Stimulated insulin sensitivity was measured using the insulin sensitivity index (ISI), a composite index derived from the OGTT and validated by Matsuda et al. 15 Total insulin secretion was assessed by AUC INS , while b-cell function relative to insulin sensitivity was assessed by oral disposition index (DIo). 16 VAI was calculated as described, 12 using the following formula differentiated according to sex, when TG is triglyceride level expressed in mM and HDL is HDL cholesterol level expressed in mM:
Men:VAI ¼½WC=39Á68þð1Á88ÂBMIÞÂðTG=1Á03ÞÂð1Á31=HDLÞ
Women:VAI¼½WC=36Á58þð1Á89ÂBMIÞÂðTG=0Á81ÞÂð1Á52=HDLÞ
After the diagnosis was made, all patients received CAB at the initial weekly dose of 0Á50 mg for the first 6 months. After this period, the CAB dose was adjusted to maintain serum PRL levels within the normal range for sex or was increased to the maximal tolerable dose for patients who did not achieve normal PRL levels or did not show significant tumour shrinkage. We considered disease control to be attained when PRL levels decreased to normal values for healthy subjects, according to gender (Fig. 1) . The mean weekly dose used during the study period was 0Á58 AE 0Á30 mg (range: 0Á25-1Á80).
Hormone and biochemical assays
Glucose and lipid (HDL, LDL and total cholesterol, triglycerides) levels were measured in our centralized laboratory by standard methods. Serum insulin was measured by ELISA (DRG Instruments GmbH, Germany). The sensitivity of the methods was 1 mIU/l. The normal insulin range (mIU/l) was 5-19. The conversion factor from conventional to SI units was 6Á945. During the entire study period, serum PRL was measured by chemiluminescent assay (Immulite 2000; Diagnostic Products, Los Angeles, CA) with a sensitivity of 3Á2 mU/l. The intra-and interassay coefficients of variation were 2Á3 and 5Á9%, respectively. Normal ranges were 38-500 and 40-354 mU/l for women and men, respectively.
Statistical analysis
The Statistical Packages for Social Sciences SPSS version 17 were used for data analysis. All quantitative variables showed normal distribution (normality of distribution was assessed by the Kolmogorov-Smirnov test). Baseline and after-treatment variables were presented as mean AE Standard Deviation (SD) for continuous variables; rates and proportions were calculated for categorical data. Differences between groups in univariate analysis were detected by the unpaired Student's t-test for continuous variables and by the chi-square test and Fisher's exact test (when appropriate) for categorical variables. The differences between paired continuous variables (before and after 12 months of therapy) were analysed by the paired Student's t-test for continuous variables and by the McNemar test for categorical variables. A P value of <0Á05 was considered statistically significant.
Results

Baseline
The hormonal and metabolic parameters of patients at diagnosis are shown in Table 1 . The mean PRL levels at diagnosis were 3715 AE 5718 mU/l with a mean tumour volume of No correlation between PRL levels and BMI, CV, VAI and other metabolic parameters at diagnosis was found (data not shown).
At 12 months of treatment
The hormonal and metabolic parameters of patients after CAB treatment are shown in Table 1 . As expected, at 12 months of treatment, a significant decrease in PRL levels (529Á2 AE 712 vs 3715 AE 5718 mU/l; P = 0Á001) and tumour volume (8Á16 AE 3Á58 vs 10Á56 AE 5Á19 mm3; P < 0Á001) was found. As a whole, 24 of 43 patients (55Á8%) were classified as controlled and 19 of 43 (44Á2%) as uncontrolled.
We found a significant increase in the prevalence of NGT (90Á7 vs 62Á8%; P = 0Á004) with a concomitant decrease in cases of IGT (7 vs 23Á3%; P = 0Á039) and a trend to reduction in the cases of IFG, although not statistically significant (2Á3 vs 11Á6%; P = 0Á218). The single case of DM diagnosed at baseline was not confirmed after 12 months of treatment. MS was detected in 6 (14%) patients versus 13 patients (30Á2%) before treatment (P = 0Á016). A significant decrease in WC (87Á13 AE 10Á15 vs 88Á81 AE 10Á48 cm; P < 0Á001), without a significant decrease in BMI (25Á41 AE 4Á97 vs 25Á57 AE 5Á18 kg/m 2 ; P = 0Á177), was also found.
As regards the lipid profile, we found a significant decrease in total cholesterol (4Á30 AE 0Á73 vs 4Á70 AE 0Á98 mM; P = 0Á001), LDL cholesterol (2Á42 AE 0Á68 vs 2Á85 AE 0Á93 mM; P < 0Á001) and triglycerides (1Á30 AE 0Á50 vs 1Á43 AE 0Á65 mM; P = 0Á024), with a concomitant significant increase in HDL cholesterol (1Á28 AE 0Á21 vs 1Á19 AE 0Á21 mM; P < 0Á001).
As regards glucose metabolism, a significant reduction in fasting insulin (86Á42 AE 25Á90 vs 117Á98 AE 46Á89 pM; P < 0Á001), AUC INS (37739 AE 11249 vs 58963 AE 21286; P < 0Á001), HbA1c (5Á18 AE 0Á43 vs 5Á36 AE 0Á62%; P = 0Á022) and Homa-IR (2Á93 AE 0Á96 vs 3Á87 AE 1Á53; P < 0Á001) with a significant increase in ISI Matsuda (4Á75 AE 1Á44 vs 3Á20 AE 1Á28; P < 0Á001) was detected (Fig. 2a) . VAI was significantly decreased (1Á94 AE 1Á01 vs 2Á36 AE 1Á32¸P < 0Á001) after 12 months of treatment (Fig. 2d) . No significant difference was found in fasting glucose (P = 0Á337), AUC GLU (P = 0Á357) and DIo (P = 0Á404) (Fig. 2g) . No correlation between PRL and BMI, CV, VAI and other metabolic parameters was found at 12 months of treatment (data not shown).
When we analysed the hormonal and metabolic parameters in patients grouped according to achievement of disease control, the two groups only differed in PRL levels (P < 0Á001) and tumour volume (P = 0Á016) ( Table 2 , Fig. 2b,e,h ).
Grouping the patients according to median weekly dose of CAB used during the 12-month-follow-up [0Á50 (0Á37-0Á75) mg], those treated with a low dose (LD: 50th centile; i.e. 0Á50 mg) were 29 (67Á4%) and those with a high dose (HD: >50th centile; i.e. >0Á50 mg) were 14 (32Á6%). No difference was found in tumour volume (P = 0Á625) or PRL levels (P = 0Á430) between the two groups. MS was found in 1 patient (7Á2%) receiving HD of CAB and in 5 patients (17Á2%) on LD (P = 0Á645). NGT, IFG and IGT were found in 26 (89Á6%) and 13 (92Á8%), 0 and 1 (7Á2%), 3 (10Á4%) and 0 patients receiving HD and LD, respectively, without significant differences between the two patient groups. The data of patients grouped according to CAB dose are shown in Table 3 . The patients receiving HD showed lower BMI (23Á12 AE 2Á71 vs 26Á51 AE 5Á45 Kg/m 2 ; P = 0Á009), fasting insulin (69Á20 AE 17Á67 vs 94Á73 AE 25Á33; P = 0Á001), Homa-IR (2Á21 AE 0Á64 vs 3Á28 AE 0Á90; P < 0Á001) and VAI (1Á31 AE 0Á44 vs 2Á07 AE 1Á11; P = 0Á018) (Fig. 2f ) compared with those receiving LD, with concomitant higher ISI Matsuda (5Á70 AE 1Á28 vs 4Á29 AE 1Á29; P = 0Á002) ( Fig. 2c) and DIo (3Á20 AE 3Á52 vs. 1Á41 AE 0Á74; P = 0Á011). (Fig. 2i) . No difference in the other metabolic parameters was found between the two groups of patients.
Discussion
The role of PRL as a metabolic hormone and the metabolic effect of DA treatment in patients with prolactinoma are not fully understood. Our data demonstrate that 12 months of CAB treatment improves most of the metabolic parameters and the degree of glucose tolerance, mainly when higher doses of CAB are used. In this study, a control group was not recruited as our aim was to evaluate the metabolic parameters during DA treatment, and for this purpose, we used patients as their own controls.
Weight gain and impaired lipid profile have frequently been associated with hyperprolactinaemia, and a link between elevated PRL levels and glucose abnormalities or hyperinsulinaemia has been well documented. [18] [19] [20] [21] The mechanisms of these associations are still poorly understood. The involvement of PRL in pancreatic b-cell and insulin production and secretion has been proposed, 22, 23 and a role of PRL in reducing lipoprotein lipase activity in adipose tissue with consequent increase in triglycerides has been demonstrated. 24 An involvement of adipokines in prolactinoma has also been suggested. It is well known that leptin plays a major role in food intake and body energy balance, 25 and Balci et al. recently demonstrated strong immunoreactivity for leptin protein in prolactinomas, assuming a cosecretion of PRL and leptin. 26 These observations could partially explain some metabolic features observed in patients with prolactinoma, such as the presence of insulin resistance, although to date discordant data are available. Indeed, no correlation between PRL and leptin levels nor a decrease in leptin during DA treatment has been observed. 11 Hypogonadism, which is frequently associated with hyperprolactinaemia, has been considered an additional possible mechanism involved in weight gain in these patients. 27 For this reason, to avoid any interference, we decided to exclude from this analysis patients with overt hypogonadism associated with prolactinoma. Recently, waist/hip ratio, lipid profile, Homa-IR and adiponectin levels were found significantly altered in 20 patients with prolactinoma with uncontrolled PRL levels compared with healthy subjects, 28 and Tuzcu et al. 29 demonstrated a state of insulin resistance in 16 patients with hyperprolactinaemia using a euglycaemic hyperinsulinaemic clamp. However, the reduced degree of insulin sensitivity described in patients with elevated PRL seems not to have any association with BMI or waist circumference. 30 Our results are in line with these findings.
Indeed, in our patients, no association between PRL levels and metabolic parameters was found either at baseline or after 12 months of treatment with CAB, and no difference in metabolic profile was found between patients with uncontrolled and controlled PRL levels during treatment. In this light, PRL seems not to be directly involved in the metabolic features of patients with prolactinoma. The absence of significant differences in metabolic parameters between patients with persistent high PRL levels and patients with controlled disease strengthens this hypothesis.
Dopamine has been shown to play a role in increased energy expenditure and downregulated food intake. 31 The reduction in dopaminergic tone associated with hyperprolactinaemia has been considered as an additional possible mechanism involved in weight gain in patients with prolactinoma, and the lower body fat content in patients that normalizes the PRL levels is likely due to dopamine receptor type 2 (DR2) activation as a result of DA treatment. 5 In this connection, it has been suggested that the DR2 gene may play a role in the regulation of weight. 32 A role of DA in glucose and lipid metabolism has been well documented both in diabetic and obese subjects, 33, 34 but most of the available data are under bromocriptine treatment. 35, 36 For these reasons, we aimed to evaluate the CAB effect on metabolic parameters. Most of the available studies have focused on metabolic parameters such as weight or BMI, highlighting the prevalence of obesity in patients with prolactinoma, 7 and the reduction in weight after the normalization of PRL levels during DA treatment 2,37 although with discordant results. 29, 38 In our cohort of patients with hyperprolactinaemia, while WC significantly decreased after treatment, BMI did not change significantly, suggesting the presence of other factors influencing the improvement in metabolic parameters. The available studies on the effect of DA on lipid metabolism are not fully consistent. 38, 39 We found a significant improvement in lipid profile, as demonstrated by the increase in HDL cholesterol and the decrease in LDL cholesterol and triglycerides, in line with the data of Berinder et al.
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The mechanisms by which DA could improve glucose metabolism may include suppression of endogenous glucose production or increased splanchnic glucose uptake after glucose ingestion. 36 A tendency to an improvement in insulin sensitivity, assessed by both ISI Matsuda and clamp, was reported after DA treatment. 9, 10 These findings are concordant with our results. Indeed, we observed a significant improvement in glucose tolerance and prevalence of MS, with a decrease in insulin levels, an improvement in insulin sensitivity indices and a concomitant reduction in HbA1c. The improvement of the sole case of DM after 12 months of treatment, without glucose lowering treatment, is in line with previous data. 10 Our data demonstrated that the relationship between the decrease in PRL levels and the improvement in insulin sensitivity and the other metabolic parameters seems to reflect the effect of CAB treatment, rather than the association between PRL and BMI. Because our patients did not show significant changes in BMI, other mechanisms seem to be involved in the beneficial effects of DA treatment on metabolic profile. In this light, the role of VAI cannot be ruled out. VAI is a sex-specific mathematical index based on anthropometric and metabolic parameters and could be considered a surrogate marker of adipose tissue function and distribution. This index has been demonstrated to be independently correlated with insulin sensitivity and cardiometabolic risk in the general population, 12 in women with polycystic ovary syndrome 40 and in newly diagnosed patients with acromegaly, where VAI significantly correlates with adipocytokine levels. 41 After CAB treatment, our patients had significantly reduced VAI. Therefore, an improvement in adipose tissue function could be considered to have a major role in the change in metabolic profile after treatment. In this light, in line with previous studies, the improvement in insulin sensitivity after DA treatment could be considered to be linked to the decrease in PRL levels, to the improvement of body composition, as demonstrated by the reduction in WC and VAI, to DA treatment or to a combination of these factors. In this connection, our data show that patients treated with HD of CAB had a more marked improvement in metabolic profile, highlighted by BMI, insulin, Homa-IR, ISI Matsuda and VAI values, than patients treated with LD. In addition, the first group of patients showed higher DIo, demonstrating a more efficient and adequate insulin secretion relative to insulin sensitivity.
In conclusion, a significant metabolic improvement is observed in patients with prolactinoma after 12 months of CAB treatment and the reason for this is probably multifactorial. Our data highlight the importance of considering the metabolic profile in these patients and the role of active treatment with high CAB doses which, besides normalizing hormonal levels, also improve metabolic parameters and insulin sensitivity indices.
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